x

Posted 17 October, 2022

ONCOSEC MEDICAL Inc appointed new CEO

CEO Change detected for ticker Nasdaq:ONCS in a 8-K filed on 17 October, 2022.


  Effective October 15, 2022, the Board of Directors (the "Board") of OncoSec Medical Incorporated (the "Company") elected Dr. Robert H. Arch, the Company's President and Chief Executive Officer, as an non-independent director of the Board.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of ONCOSEC MEDICAL Inc
Health Care/Life Sciences • Pharmaceuticals
OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in Ewing, NJ.
Market Cap
$0.60K
View Company Details
ONCOSEC MEDICAL Inc by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Effective October 15, 2022, the Board of Directors (the "Board") of OncoSec Medical Incorporated (the "Company") elected Dr. Robert H. Arch, the Company's President and Chief Executive Officer, as an non-independent director of the Board.


Dr. Arch will not be compensated for his service on the Board in accordance with the Company's compensatory and other arrangements for directors who are also employees of the Company except for reimbursement for reasonable out-of-pocket expenses incurred in attending Board or Board committee meetings or otherwise in connection with performance of his duties as a director of the Company, which are described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on May 31, 2022.


There are no transactions between Dr. Arch and the Company that would require disclosure under Item 404(a) of Regulation S-K.


There are no arrangements or understandings between Dr. Arch and any other persons pursuant to which Dr. Arch was appointed as a director of the Company.